Bristol-Myers Squibb Company today announced that its Board of Directors has elected Peter J. Arduini to the Board, effective April 1, 2016. Mr. Arduini will serve as a member of the Audit Committee of the Board of Directors, effective May 3, 2016.
Mr. Arduini, 51, is currently president and chief executive officer and director of Integra LifeSciences, a leading global medical technology company. He joined Integra LifeSciences in 2010 as president and chief operating officer and director, and was named CEO in 2012. Mr. Arduini brings more than 25 years of global experience in medical device technology and pharmaceutical businesses, and has led operations in China, Europe, Japan and the U.S. Before joining Integra, Mr. Arduini was corporate vice president and president of Medication Delivery, Baxter Healthcare, which he joined in 2005. At Baxter, he was responsible for a portfolio focused on the inpatient acute care hospital market. Prior to joining Baxter, Mr. Arduini was responsible for the functional imaging business at General Electric Healthcare, where he spent 15 years assuming increasing levels of responsibility. Mr. Arduini serves on the Board of Directors of ADVAMED, the Advanced Medical Technology Association, and MDIC, the Medical Device Innovation Consortium. Mr. Arduini received his bachelor’s degree in marketing from Susquehanna University and a master’s in management from Northwestern University’s Kellogg School of Management.
“Pete is a confident and engaging leader who has delivered tremendous results throughout his career,” said Lamberto Andreotti, chairman, Bristol-Myers Squibb. “His commercial, financial and operational experience, along with a deep understanding of healthcare, make him an ideal choice for our Board. I look forward to his contributions.”
“Pete brings significant healthcare experience, unwavering integrity and a focus on helping patients,” said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. “Bristol-Myers Squibb will benefit from his insights as a strategic leader, and I am excited to have him join our Board.”
Source: Bristol-Myers Squibb
Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.
The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.
In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.